2 Gurus Talk Compliance: Episode 55 – The From Worse to Worser Edition
First 100 Days of the New HSR Rules with Antitrust Partner Kara Kuritz
The LathamTECH Podcast — Getting Deals Done: Tackling Antitrust Challenges in Tech M&A
Daily Compliance News: June 2, 2025, The Unintended Consequence Edition
Podcast - Navigating the New Landscape of Private Equity in Healthcare
10 For 10: Top Compliance Stories For the Week Ending May 17, 2025
From Cell Phones to Tractors: The Right to Repair Movement Drives On — Regulatory Oversight Podcast
Daily Compliance News: May 12, 2025, The Corruption in the Broad Daylight Edition
Daily Compliance News: May 1, 2025, The 100 Days of Corruption Edition
Daily Compliance News: April 23, 2025, The R-E-S-P-E-C-T Edition
Business Better Podcast Episode: Bridging Campuses: Legal Insights on Education Industry Consolidation – Mergers, Acquisitions, and Antitrust
Antitrust Insights for Private Equity Navigating the New Administration's Policies — PE Pathways Podcast
12 Days of Regulatory Insights: Day 11 – State AGs on the Antitrust Frontline — Regulatory Oversight Podcast
12 Days of Regulatory Insights: Day 8 - Inside the Texas AG's Office — Regulatory Oversight Podcast
12 Days of Regulatory Insights: Day 3 - State AG Oversight in the Health Care Industry — Regulatory Oversight Podcast
Episode 341 -- DOJ Charges Visa with Monopolization and Exclusionary Conduct in the Debit Card Market
Fierce Competition Podcast | Antitrust Challenges in Organized Sports: How They Play Out in the EU, UK and US
Podcast: Key Changes in Finalized Antitrust Merger Guidelines – Diagnosing Health Care
The Changing Landscape of State AG Antitrust Enforcement — Regulatory Oversight Podcast
Fierce Competition Podcast | Takeaways From the Illumina-Grail Merger Challenge Saga
Antitrust scrutiny of healthcare markets is nothing new. The Biden Administration and first Trump Administration focused antitrust enforcement efforts across the healthcare and life sciences industries. The newly installed...more
Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that could affect biotech, pharmaceutical, and medical device companies in coming...more